Introduction
============

Several methods exist for improving transdermal drug delivery such as chemical mediation using liposomes or chemical enhancers, and physical mechanisms such as iontophoresis, lasers, electroporation, microneedles and ultrasound (also called sonophoresis or phonophoresis) ([@b72-ijn-2-585]; [@b73-ijn-2-585]; [@b63-ijn-2-585]; [@b100-ijn-2-585]; [@b66-ijn-2-585]). Numerous studies of these methods have shown that ultrasound mediated transdermal drug delivery offers promising potential for noninvasive drug administration. However the broad literature on ultrasound drug delivery is not confined only to transdermal applications. A large body of work focuses specifically on delivery to internal organs, but does not cover tissues or gene delivery. Additionally for transdermal work, the reader is also directed to several well written articles for further reading and additional viewpoints on this topic ([@b61-ijn-2-585]; [@b71-ijn-2-585]; [@b13-ijn-2-585]).

Passive drug delivery across the stratum corneum can be transported with molecules that have a weight less than 500 Da ([@b13-ijn-2-585]). In general the stratum corneum, which varies in thickness (≈ 10--20 μm) depending on the body location, forms the barrier to drug diffusion. This low permeability is attributed to the outermost skin layer that consists of a compact and organized structure of cells named keratinocites surrounded by lipid bilayers. Ultrasound enhanced transdermal drug delivery offers advantages over traditional injection drug delivery methods which are invasive and painful. Currently few drugs, proteins or peptides have been successfully administered transdermally for clinical applications because of the low skin permeability to these relatively large molecules. However from a research viewpoint, the list of compounds which have been shown to transdermally cross skin via ultrasound is ever increasing. One hypothesis indicates that once the drug has traversed the stratum corneum, the next layer is easier to cross and subsequently the drug can reach the capillary vessels to be absorbed ([@b53-ijn-2-585]).

Background on ultrasound delivery and biological effects
========================================================

One of the earliest reports of the interaction between ultrasound and biological tissue can be traced back to the 1920s and the post-World War I experiments of Professor Paul Langévin ([@b27-ijn-2-585]). Much of his work centered on the development of pulse-echo sonar for submarine detection, including the observation of bubble formation in the water and the killing of fish from the sound beam. Specific biological changes such as searing of skin, rupturing of red blood cells and lethal effects on mammals were observed by Wood and Loomis with 200--500 kHz high intensity ultrasound ([@b103-ijn-2-585]).

In contrast to ultrasound used for diagnostic imaging, therapeutic ultrasound can be described as a controlled sound wave intended for biological interaction for a curative benefit. Some of the first clinically significant application of this technology was developed by Francis and William Fry in the 1950s ([@b24-ijn-2-585]; [@b23-ijn-2-585]). Their work was applied to the development of ultrasound devices for noninvasive surgical treatment of neurological disorders including Parkinson disease. Results included both reversible and irreversible biological effects. Other early clinical applications at this same time include the treatment of arthritis using ultrasound with hydrocortisone to relieve pain ([@b21-ijn-2-585]).

Thus it is appropriate to divide therapeutic ultrasound into two categories which use 'low' intensities and 'high' intensities (\>5 W/cm^2^) though this division is not precise ([@b89-ijn-2-585]). High intensity focused ultrasound (HIFU) is an attractive means of noninvasive coagulation of deep tissues using external sources. Current clinical applications of ultrasound include transducer and array designs for the treatment of prostate cancer ([@b25-ijn-2-585]; Saleh and Smith 2004), liver tumors ([@b47-ijn-2-585]; [@b26-ijn-2-585]), breast cancer ([@b32-ijn-2-585]; [@b104-ijn-2-585]), bladder tumors ([@b99-ijn-2-585]; [@b48-ijn-2-585]) and uterine fibroids (Chan et al 2002; [@b88-ijn-2-585]). Low intensity ultrasound has been shown to mediate the transport of drugs across the skin and is clinically used in physical therapy to accelerate or stimulate a normal biological response through deep heating.

Many recent reviews have shown that ultrasound mediated transdermal drug delivery offers promising potential for noninvasive drug administration ([@b85-ijn-2-585]; [@b71-ijn-2-585]; [@b52-ijn-2-585]). The working principle of sonophoresis, although not completely understood, has been suggested to be the result of cavitation ([@b53-ijn-2-585], [@b55-ijn-2-585]) although thermal effects can not be entirely discounted. Low frequency ultrasound is capable of generating microbubbles in the water and tissue. Because sound energy is transmitted in a fluid media, the large negative pressures cause violent collapse in bubbles, which results in the formation of water channels within the lipid bilayers. The resulting disorder created in the stratum corneum facilitates the crossing of a hydrophilic drug or molecule.

[Table 1](#t1-ijn-2-585){ref-type="table"} sets out an overview of the transdermal ultrasound mediated drug delivery literature from the past several years with some commentary on notable contributions. Though not complete, the table lists the delivered compound or drug, its respective molecular weight (Daltons) and the experimental sample (animal) preparation including whether the experiment was performed under in vivo or in vitro conditions. Of major interest is the ability to reduce the research to clinical practice and therefore the reported ultrasound frequency and device is listed. For the table, ultrasound devices can be classified into different categories. The commercially made devices include sonicators (≈20 kHz), ultrasound heating devices intended for therapy (\>1 MHz) and pre-fabricated transducers. Very few of the ultrasound devices listed are specifically designed for drug delivery and originally, like the sonicator, had a different intended purpose.

Many previous investigators using sonophoresis have found enhanced transdermal drug delivery over various frequency ranges using commercial sonicators or therapeutic devices. For example, a 14-fold increase of corticosterone transport has been shown using a 1 MHz therapeutic product used for the treatment of chronic and acute pain (Sonopuls^®^ 463, Sugarland, TX) operating at 1.4 W/cm^2^ for 24 hours ([@b33-ijn-2-585]). Significant transdermal transport of model drugs such as mannitol and inulin (plant starch) has been observed using a 20 kHz commercial sonicator (VCX400, Sonics and Materials, Newtown, CT) ([@b44-ijn-2-585]). Previous work with high frequency ultrasound (≈1 MHz and at 1--3 W/cm^2^) to enhance transdermal drug delivery has produced interesting results, which varied from drug to drug (Bommannan et al 1992a, 1992b; [@b55-ijn-2-585]). Pulsed ultrasound at 1 MHz has been used to increase transdermal absorption of indomethacin from an ointment in rats ([@b6-ijn-2-585]). A combination of chemical enhancers and therapeutic ultrasound (1 MHz, 1.4 W/cm^2^, continuous wave (CW)) in transdermal drug transport has also been investigated with success ([@b33-ijn-2-585]).

A noteworthy difference between high (1--3 MHz) and low (≈20 kHz) frequency ultrasound appears to be that low frequency ultrasound enhances transdermal drug transport 1000 times more than high frequency ultrasound ([@b54-ijn-2-585]). The working hypothesis for the physical mechanism is that low-frequency ultrasound enhances transdermal transport through aqueous channels in the *stratum corneum* generated by cavitation induced bilayer disordering. However, the mechanism of the enhancement using ultrasound is far from being fully understood ([@b71-ijn-2-585]). Some researchers have concluded that at 168 kHz using CW ultrasound and at 1.9^\*^ × 10^5^ Pa, a new structural state was induced which generated defects in human stratum corneum specimens. They suggest that the dimensions of the defects (20 μm) were large enough to allow the transdermal passage of high molecular weight drug molecules, which normally elude the unenhanced transdermal drug delivery ([@b105-ijn-2-585]).

Past research has demonstrated the possibility of delivering and controlling therapeutic doses of proteins such as interferon gamma and erythropoeitin across human skin using ultrasound ([@b53-ijn-2-585]). Other researchers have investigated the in vitro penetration and the in vivo transport of flufenamic acid in skin with ultrasound ([@b29-ijn-2-585]). In the flufenamic acid study, ultrasound exposure was from 5--30 minutes with intensities up to 1.5 W/cm^2^. Although there was a pronounced effect of ultrasound on the transmembrane absorption of the drug, there was also a rise in temperature up to 4.5 °C. Ultrasound at 1 MHz has also been used to enhance the transdermal absorption of indomethacin studied in rats using intensities from 0.25--1 W/cm^2^. The researchers reported no significant skin temperature rise and no notable damage to the skin, although damage was noted as the intensity and the time of application of ultrasound increased beyond 1 W/cm^2^ ([@b62-ijn-2-585]).

Other researchers have reported noticeable skin damage from ultrasound transdermal drug delivery experiments ([@b105-ijn-2-585]). One group has examined the morphological changes induced in in vitro hairless mouse skin and human skin after ultrasound exposure to transdermal drug delivery systems. The skins were immersed in a commercial ultrasound water tank at 48 kHz and an intensity of 0.5 W/cm^2^. Skins were compared to control skins under a scanning electron microscope. The researchers found that cells of the stratum corneum of the mouse skin surface were almost completely removed. Furthermore, on some of the the mouse samples, large craterlike pores with a diameter of 100 microns were formed sporadically. However in human skin, the surface exposed to ultrasound showed only slight removal of keratinocytes around the hair follicles. The researchers suggested that the removal of the stratum corneum and other alterations in hairless mouse and human skin may explain the enhancement of transdermal drug penetration ([@b106-ijn-2-585]).

Convenient noninvasive methods for transdermal delivery of insulin or similar procedures for glucose sensing has particular public interest due to the increasing problem of diabetes. In the United State alone, approximately 16 million people suffer from diabetes mellitus. From a human and economic perspective, it is one of the most costly diseases (Congressionally Established Diabetes Research Working Group 1999; [@b95-ijn-2-585]). Management of diabetes often requires painful repetitive blood glucose tests and insulin injections up to three or four times each day. Between injections, blood sugar levels can fluctuate and remain out of balance until the next test or injection, increasing the risk of tissue or organ damage.

Specifically for insulin ([Table 1](#t1-ijn-2-585){ref-type="table"}), the amount of research for noninvasive insulin delivery is increasing every year. Over a frequency range of 20--105 kHz, enhanced transport in the presence of ultrasound has been shown in both in vitro and in vivo experiments. Many early experiments were performed using either an ultrasound sonicator, ultrasonic bath or commercial transducer. For example investigators have demonstrated effective in vivo transport of insulin at 48 kHz using an ultrasonic bath ([@b84-ijn-2-585]) and at 105 kHz ([@b83-ijn-2-585]) using a commercially obtained transducer. The major drawback so far in exploiting ultrasound for noninvasive drug delivery is the large size and poor mobility of the ultrasound device. Commercial sonicators are large, heavy, table-top devices specifically designed for lysis of cells, catalyzing reactions, creating emulsions or cleaning. A few commercial ultrasound devices do exist, specifically designed for ultrasound drug delivery, such as the SonoPrep^®^ made by the Sontra Medical Corporation (Cambridge MA), which is a large ultrasound device that consists of a power control unit and a hand-held applicator.

Although diabetics have an aversion to injecting insulin they probably hate the more frequent finger-stick for blood glucose samples even more. A number of different techniques for monitoring blood glucose using non-invasive or minimally invasive methods are under investigation including near-infrared spectroscopy, implantable glucose sensors, reverse sonophoresis, reverse iontophoresis and interstitial fluid sampling devices ([@b35-ijn-2-585]). The latter three techniques extract glucose transdermally and measure glucose in interstitial fluid. Dermal interstitial fluid glucose concentration is highly correlated with the plasma glucose concentration and capillary blood glucose concentration. Thus transdermal extraction of interstitial fluid offers a noninvasive method of obtaining a sample for blood glucose measurements ([@b16-ijn-2-585]; [@b35-ijn-2-585]). Previous results has demonstrated positive results in the use of ultrasound to facilitate the noninvasive extraction of interstitial skin fluids (ISF) for blood glucose monitoring through an electrolytic reaction with glucose sensitive enzymes ([@b36-ijn-2-585]).

Mechanism of ultrasound
=======================

Although ultrasound is known to increase transdermal protein delivery ([@b83-ijn-2-585]; [@b53-ijn-2-585]a) the mechanisms of this enhanced transport have not been fully characterized ([@b71-ijn-2-585]). Bioeffects from ultrasound include the thermal or mechanical (cavitation) mechanism ([@b1-ijn-2-585]). One effect of cavitating ultrasound is its ability to increase permeability of the outer skin layer (stratum corneum), which is thought to be a primary barrier to protein diffusion. Cavitation represents the rapid expansion and collapse of gaseous bubbles in response to an alternating pressure field. Cavitation types can be broken into two non-exclusive categories ([@b22-ijn-2-585]). The first is stable cavitation where the cavity oscillates about its equilibrium radius in response to relatively low acoustic pressures. The second is transient cavitation (also known as inertial cavitation) whereby the equilibrium size varies greatly in response to very few acoustic cycles. During transient cavitation, the rapid, violent collapse of bubbles is associated with high acoustic pressures and temperatures of the order of 1000--2000 K ([@b3-ijn-2-585], [@b4-ijn-2-585]). Transient cavities are generated in response to high acoustic pressures and/or lower frequencies. The violent hydrodynamic forces ([Figure 1](#f1-ijn-2-585){ref-type="fig"}) due to a collapsing bubble can cause severe damage within biological media. Indeed free radicals can be produced by this violent phenomena ([@b20-ijn-2-585]; [@b49-ijn-2-585]).

There exists several definitions for the threshold for transient cavitation in terms of such physical parameters as acoustic pressure, frequency or bubble radius. For diagnostic ultrasound, one (of many) definitions of the cavitation onset is the peak rarefractional pressure divided by the square root of the frequency ([@b5-ijn-2-585]). From previous research, the measured cavitation pressure amplitude in dog thigh muscle in vivo was found to depend linearly on frequency with a slope of 5.3 MPa/MHz ([@b31-ijn-2-585]). Compared to the kilohertz range, ultrasound in the megahertz range also produces cavitation although much higher pressures are required to exceed the cavitation threshold. Beyond the threshold, cavitation has been shown to disrupt cells and damage tissue ([@b17-ijn-2-585]; [@b51-ijn-2-585]). Mechanical bioeffects in tissues with gas bodies include lung hemorrhage in mice, rats, monkeys and pigs ([@b1-ijn-2-585]). Cavitation has also been shown with diagnostic ultrasound levels ([@b4-ijn-2-585]; [@b75-ijn-2-585]) which has motivated the introduction of the mechanical index to identify a threshold pressure for the onset of inertial cavitation ([@b2-ijn-2-585]). Even in the absence of well-defined gas bodies, there exist non-thermal bioeffects due to ultrasound, which are known to occur in the absence of excessive heating or evidence of cavitation bubbles. In this situation, the mechanism is in the form of radiation force or torque or acoustic streaming ([@b7-ijn-2-585]).

The dynamics of acoustic cavitation in liquid alone differ considerably to cavitation at liquid-solid interfaces. Ultimately acoustic bubble dynamics are quite complex and beyond this overview ([@b3-ijn-2-585]; [@b43-ijn-2-585]; [@b28-ijn-2-585]). Determining the threshold and energy from a cavitation event is difficult under the best conditions. Researchers in ultrasound try to follow three experimental rules with respect to cavitation: understand the liquid including impurities, understand the sound field, and know when something happens ([@b3-ijn-2-585]). The first rule refers to the cavitation threshold while the second rule relates to accurate measurements of the acoustic field. The third relates to observable cavitation events or secondary related information. Rule two deals with a commentary regarding information which could have been included in [Table 1](#t1-ijn-2-585){ref-type="table"} but was intentionally omitted. Though many of the papers listed in [Table 1](#t1-ijn-2-585){ref-type="table"} report an ultrasound intensity, the drawback is that much of the literature gives a value but does not specify details of the exposimetry such as spatial (average, peak) or temporal (average, peak) values. To report the determination of an acoustic field, it is essential to supply enough information, such as calibrated hydrophones, dissolved gas concentration, anechoic conditions, etc., so that intensity experiments can be repeated by others. Therefore accurate and precise evaluation of acoustic fields should follow exposimetry and dosimetry procedures previously recognized in the ultrasound literature ([@b78-ijn-2-585]; [@b45-ijn-2-585]; [@b2-ijn-2-585]; [@b46-ijn-2-585]). Without such information, comparing the intensity of enhanced transport between many of the drug delivery publications, or determining potential bioeffects, is impossible.

Future of transdermal drug delivery
===================================

Use of transdermal drug delivery techniques has the most practical clinical application for medications which need to be injected multiple times either daily or weekly. Though infrequent, other injectable drug avoidance situations could include the use of needles on infants, children and pets or under harsh conditions (battlefield or first responder) where needles are not feasible. As seen in [Table 1](#t1-ijn-2-585){ref-type="table"}, many previous researchers who have successfully used acoustic energy for drug delivery have used commercial sonicators or off-the-shelf transducers. These large industrial devices are impractical for a feasible and transportable drug delivery device. Much of the previous ultrasound transdermal dry delivery research has focused on low frequencies primarily because commercial sonicators were designed to operate only at one frequency. To bring this research to clinical practice will require more investigation into the optimal frequency and intensity of each particular drug. As with diagnostic ultrasound imaging, drug delivery using ultrasound requires a delicate balance between safety and efficacy and requires careful scientific study.

Other recent reviews on drug delivery state similar views to those expressed here, for example, "small-sized low-frequency transducers need to be developed so that patients can wear them" ([@b71-ijn-2-585]). Although there are several possible low frequency transducer designs that can be used in a drug delivery application, such as the low frequency flextensional resonators ([@b81-ijn-2-585]), tonpilz transducers ([@b102-ijn-2-585]), or "thickness"-type resonators ([@b79-ijn-2-585]), the "cymbal" transducer design is a good choice for a portable device. This Class V flextensional transducer has a thickness of less than 2 mm, weighs less than 3 g, resonates between 1 and 100 kHz depending on geometry, and has a large scale manufacturing cost of less than \$5.00/unit ([@b67-ijn-2-585], [@b68-ijn-2-585]; [@b19-ijn-2-585]; Newnham, 1998; [@b97-ijn-2-585]). With the low profile cymbal design, high frequency radial motions of the ceramic translates into low frequency displacement motions through the cap covered cavity. If the diameter of the ceramic is increased (ie, a larger single element), then the frequency of the transducer decreases towards a lower range. If the diameter increased, the capsule depth of the flextensional design also needs to increase thereby increasing the thickness and slightly increasing the profile. Cymbals can be arranged into multi-element array designs ([Figure 2](#f2-ijn-2-585){ref-type="fig"}) since this can increase the effective aperture of ultrasound area with respect to skin area. Some research indicates that the delivery dose increases with ultrasound exposure area ([@b80-ijn-2-585]). Interestingly the cymbal design originates from underwater research for naval applications and current research is underway to incorporate existing battery technology in the miniaturization of portable power for both insulin delivery and glucose sensing ([@b41-ijn-2-585], [@b40-ijn-2-585]).

In general the future for noninvasive drug delivery is encouraging. Exploiting transdermal ultrasound drug delivery beyond the feasibility stage will require the cooperation of medical doctors and engineers so that the technology aids the construction of a clinical device. As with diagnostic ultrasound, the bioeffects and safety of each device needs to be carefully monitored, because it will not matter how much of any drug can be transported if the skin is burned, damaged or the procedure is painful.
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![With transient cavitation the bubble dynamics have two basics stages comprising the initial formations of the cavity followed by the growth and asymmetric violent collapse. The photo shows the jet produced by the collapse of a cavitation bubble at a liquid-solid interface. \[Photo courtesy of Dr. Lawrence Crum at the University of Washington.\]](ijn-2-585f1){#f1-ijn-2-585}

![The future of practical noninvasive drug delivery may be in the use of novel transducers or ceramics for producing ultrasound. One example is the cymbal transducer made of piezoelectric material PZT-4 operated at a frequency of 20 kHz. The light-weight, low-profile array was constructed using cymbal transducers which were connected in parallel, and encased in URALITE^®^ polymer. The dimensions of the array were 37 × 37 × 2 mm^3^ and is comparable in size to a US quarter; it weighed less than 22 g.](ijn-2-585f2){#f2-ijn-2-585}

###### 

A list of transdermally delivered drugs and compounds using ultrasound devices

  **Compound**                                            **M.W**   **Preparation**                **Frequency**                      **Device**                                                  **Investigator**
  ------------------------------------------------------- --------- ------------------------------ ---------------------------------- ----------------------------------------------------------- ---------------------
  Aldosterone                                             832       in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b33-ijn-2-585])
  Benzene                                                 78        in vitro human                 1--3 MHz                           Therapeutic[5](#tfn6-ijn-2-585){ref-type="table-fn"}        ([@b53-ijn-2-585])
  Bicarbonate                                             136       in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b56-ijn-2-585])
  Butanol                                                 74        in vitro human                 1--3 MHz                           Therapeutic[5](#tfn6-ijn-2-585){ref-type="table-fn"}        ([@b53-ijn-2-585])
  Butanol                                                 74        in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b33-ijn-2-585])
  Caffeine                                                194       in vitro human                 1--3 MHz                           Therapeutic[5](#tfn6-ijn-2-585){ref-type="table-fn"}        ([@b53-ijn-2-585])
  Caffeine                                                194       in vitro human                 20 kHz                             +++                                                         ([@b11-ijn-2-585])
  Caffeine                                                194       in vitro rat                   20 kHz                             +++                                                         ([@b11-ijn-2-585])
  Calcein                                                 623       in vitro rat                   41, 158, 445 kHz                   US transducer[13](#tfn14-ijn-2-585){ref-type="table-fn"}    ([@b65-ijn-2-585])
  Calcein                                                 623       in vitro cell membrane         20, 57, 76, 93 kHz                 US transducer[17](#tfn18-ijn-2-585){ref-type="table-fn"}    ([@b82-ijn-2-585])
  Calcein                                                 623       in vitro porcine               20 kHz                             US transducer[21](#tfn21-ijn-2-585){ref-type="table-fn"}    ([@b98-ijn-2-585])
  Calcein                                                 623       in vitro pig                   20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b39-ijn-2-585])
  Calcein                                                 623       in vitro rat                   41 kHz                             US transducer[10](#tfn10-ijn-2-585){ref-type="table-fn"}    ([@b64-ijn-2-585])
  Calcium                                                 40        in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b56-ijn-2-585])
  Corticosterone                                          346       in vitro human                 1 MHz                              Therapeutic US[2](#tfn3-ijn-2-585){ref-type="table-fn"}     ([@b33-ijn-2-585])
  Corticosterone                                          346       in vitro human                 1--3 MHz                           Therapeutic US[5](#tfn6-ijn-2-585){ref-type="table-fn"}     ([@b53-ijn-2-585])
  Corticosterone                                          346       in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b33-ijn-2-585])
  Dexamethasone                                           392       in vitro human                 1 MHz                              Therapeutic US[2](#tfn3-ijn-2-585){ref-type="table-fn"}     ([@b33-ijn-2-585])
  Dexamethason                                            392       in vivo human                  1 MHz                              US transducer[10](#tfn11-ijn-2-585){ref-type="table-fn"}    ([@b18-ijn-2-585])
  Dextran^++^                                             2000      in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b56-ijn-2-585])
  Dextran                                                 70000     in vitro pig                   58 kHz                             US transducer[17](#tfn18-ijn-2-585){ref-type="table-fn"}    ([@b93-ijn-2-585])
  Diclofenac                                              296       in vivo human                  1 MHz                              Therapeutic                                                 ([@b74-ijn-2-585])
  Diclofenac                                              296       in vivo rat                    1 MHz                              Sonicator[12](#tfn13-ijn-2-585){ref-type="table-fn"}        ([@b30-ijn-2-585])
  Erythropoeitin                                          48000     in vitro human,                20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b53-ijn-2-585])
  Estradiol                                               272       in vitro human                 1 MHz                              Therapeutic US[2](#tfn3-ijn-2-585){ref-type="table-fn"}     ([@b33-ijn-2-585])
  Estradiol                                               272       in vitro human                 1--3 MHz                           Therapeutic US[5](#tfn6-ijn-2-585){ref-type="table-fn"}     ([@b53-ijn-2-585])
  Estradiol                                               272       in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b54-ijn-2-585])
  FD-4[\*](#tfn26-ijn-2-585){ref-type="table-fn"}         4400      in vitro rat                   41 kHz                             US transducer[10](#tfn10-ijn-2-585){ref-type="table-fn"}    ([@b64-ijn-2-585])
  FD-40[\*](#tfn26-ijn-2-585){ref-type="table-fn"}        38000     in vitro rat                   41 kHz                             US transducer[10](#tfn10-ijn-2-585){ref-type="table-fn"}    ([@b64-ijn-2-585])
  Fentanyl                                                336       in vitro human                 20 kHz                             +++                                                         ([@b11-ijn-2-585])
  Fentanyl                                                336       in vitro rat                   20 kHz                             [+++](#tfn25-ijn-2-585){ref-type="table-fn"}                ([@b11-ijn-2-585])
  FITC[\*\*\*\*](#tfn28-ijn-2-585){ref-type="table-fn"}   51000     in vitro human                 20 kHz                             Sonifier[19](#tfn20-ijn-2-585){ref-type="table-fn"}         ([@b101-ijn-2-585])
  FITC[\*\*\*\*](#tfn28-ijn-2-585){ref-type="table-fn"}   2500      in vitro human                 20 kHz                             Sonifier[19](#tfn20-ijn-2-585){ref-type="table-fn"}         ([@b101-ijn-2-585])
  Fluorescein                                             389       in vitro human                 20 kHz                             Sonicator[14](#tfn15-ijn-2-585){ref-type="table-fn"}        ([@b15-ijn-2-585])
  Fluorescein probes nile red                             535       in vitro porcine               20 kHz                             US transducer[21](#tfn21-ijn-2-585){ref-type="table-fn"}    ([@b98-ijn-2-585])
  Glucose                                                 182       in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b56-ijn-2-585])
  Glucose                                                 182       in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b37-ijn-2-585])
  Glucose                                                 182       in vitro porcine               10 MHz                             US transducer[20](#tfn21-ijn-2-585){ref-type="table-fn"}    ([@b50-ijn-2-585])
  Glucose                                                 182       in vitro porcine               20 kHz                             Sonicator[21](#tfn21-ijn-2-585){ref-type="table-fn"}        ([@b50-ijn-2-585])
  Glucose                                                 182       in vivo rat                    20 kHz                             cymbal TDR                                                  ([@b40-ijn-2-585])
  Hyaluronan                                              1000      in vivo rabbit                 1 MHz                              Therapeutic                                                 ([@b70-ijn-2-585])
  Hydrocortisone                                          362       in vivo rat                    1 MHz                              Therapeutic                                                 ([@b34-ijn-2-585])
  Ibuprofen                                               206       in vivo human                  1 MHz                              UStransducer[23](#tfn24-ijn-2-585){ref-type="table-fn"}     ([@b38-ijn-2-585])
  Insulin                                                 5807      in vitro human, in vivo rat    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b53-ijn-2-585])
  Insulin                                                 5807      in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b12-ijn-2-585])
  Insulin                                                 5807      in vivo rat                    48 kHz                             LAG-26[4](#tfn5-ijn-2-585){ref-type="table-fn"}             ([@b84-ijn-2-585])
  Insulin                                                 5807      in vivo rabbit                 105 kHz                            LAG-26[4](#tfn5-ijn-2-585){ref-type="table-fn"}             ([@b83-ijn-2-585])
  Insulin                                                 5807      in vivo rabbit                 105 kHz                            UStransducer[10](#tfn10-ijn-2-585){ref-type="table-fn"}     ([@b83-ijn-2-585])
  Insulin                                                 5807      in vitro human                 20 kHz                             Sonicator[6](#tfn7-ijn-2-585){ref-type="table-fn"}          ([@b108-ijn-2-585])
  Insulin                                                 5807      in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b10-ijn-2-585])
  Insulin                                                 5807      in vitro human                 20 kHz                             cymbal TDR                                                  ([@b80-ijn-2-585])
  Insulin                                                 5807      in vivo rat                    20 kHz                             cymbal TDR                                                  ([@b42-ijn-2-585])
  Insulin                                                 5807      in vivo rabbit                 20 kHz                             cymbal TDR                                                  ([@b42-ijn-2-585])
  Inulin                                                  5000      in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b60-ijn-2-585])
  Inulin                                                  5000      in vitro pig                   58 kHz                             US transducer[17](#tfn18-ijn-2-585){ref-type="table-fn"}    ([@b93-ijn-2-585])
  Ketoprofen                                              254       in vivo human                  1 MHz                              Sonicator[22](#tfn23-ijn-2-585){ref-type="table-fn"}        ([@b14-ijn-2-585])
  Ketorolac-tromethamine                                  376       in vitro rat                   1 MHz                              Sonicator[7](#tfn8-ijn-2-585){ref-type="table-fn"}          ([@b96-ijn-2-585])
  Lanthanum droxide                                       189       in vivo guinea pigs            2, 10, 16 MHz                      Panametrics[3](#tfn4-ijn-2-585){ref-type="table-fn"}        ([@b9-ijn-2-585])
  Lidocaine                                               234       in vitro human                 1 MHz                              Therapeutic[2](#tfn3-ijn-2-585){ref-type="table-fn"}        ([@b33-ijn-2-585])
  Linoleic acid                                           280       in vitro human                 1 MHz                              Therapeutic[2](#tfn3-ijn-2-585){ref-type="table-fn"}        ([@b33-ijn-2-585])
  Luteinizing hormone                                     1311      in vitro pig                   58 kHz                             US transducer[17](#tfn18-ijn-2-585){ref-type="table-fn"}    ([@b93-ijn-2-585])
  Mannitol                                                183       in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b60-ijn-2-585])
  Mannitol                                                183       in vitro pig                   20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b56-ijn-2-585])
  Mannitol                                                183       in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b60-ijn-2-585])
  Mannitol                                                183       in vitro pig, in vitro human   20 kHz                             US transducer[1](#tfn2-ijn-2-585){ref-type="table-fn"}      ([@b87-ijn-2-585])
  Mannitol                                                183       in vitro pig, in vivo pig      20 kHz                             US transducer[1](#tfn2-ijn-2-585){ref-type="table-fn"}      ([@b86-ijn-2-585])
  Mannitol                                                183       in vitro pig                   20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b90-ijn-2-585])
  Mannitol                                                182       in vitro pig                   58 kHz                             US transducer[17](#tfn18-ijn-2-585){ref-type="table-fn"}    ([@b93-ijn-2-585])
  Mannitol                                                183       in vitro porcine               10 MHz                             US transducer[20](#tfn21-ijn-2-585){ref-type="table-fn"}    ([@b50-ijn-2-585])
  Mannitol                                                183       in vitro porcine               20 kHz                             Sonicator[21](#tfn21-ijn-2-585){ref-type="table-fn"}        ([@b50-ijn-2-585])
  Methylpredni-solone/cyclosporine                        374       in vivo human                  25 kHz                             Sonicator[7](#tfn8-ijn-2-585){ref-type="table-fn"}          ([@b77-ijn-2-585])
  Oligonucleotides                                        +++       in vitro pig                   20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          (Tezel et al 2004)
  Progesterone                                            274       in vitro human                 1--3 MHz                           Therapeutic[5](#tfn6-ijn-2-585){ref-type="table-fn"}        ([@b53-ijn-2-585])
  Salicylic acid                                          138       in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b33-ijn-2-585])
  sodium lauryl sulfate                                   288       in vitro pig                   19.6, 36.9, 58.9, 76.6, 93.4 kHz   US transducer[17](#tfn18-ijn-2-585){ref-type="table-fn"}    ([@b94-ijn-2-585])
  sodium lauryl sulfate                                   288       in vitro pig                   20 kHz                             US transducer[11](#tfn12-ijn-2-585){ref-type="table-fn"}    ([@b91-ijn-2-585])
  sodium lauryl sulfate                                   288       in vitro porcine               20 kHz                             Sonicator[11](#tfn12-ijn-2-585){ref-type="table-fn"}        ([@b69-ijn-2-585])
  Sucrose                                                 342       in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b33-ijn-2-585])
  Sucrose                                                 342       in vitro human, pig            20 kHz                             US transducer[1](#tfn2-ijn-2-585){ref-type="table-fn"}      ([@b87-ijn-2-585])
  Testosterone                                            288       in vitro human                 1 MHz                              Therapeutic[2](#tfn3-ijn-2-585){ref-type="table-fn"}        ([@b33-ijn-2-585])
  Tetanus Toxoid (TTx vaccine)                            150000    in vivo mice                   20 kHz                             600W Sonicator[11](#tfn12-ijn-2-585){ref-type="table-fn"}   ([@b92-ijn-2-585])
  Triamcinolone- Acetonide                                434       in vitro mice                  1, 3 MHz                           US transducer[10](#tfn10-ijn-2-585){ref-type="table-fn"}    ([@b107-ijn-2-585])
  Urea                                                    60        in vivo rat                    20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b56-ijn-2-585])
  Vasopressin                                             1056      in vitro human                 20 kHz                             Sonicator[6](#tfn7-ijn-2-585){ref-type="table-fn"}          ([@b108-ijn-2-585])
  Water                                                   18        in vitro human                 20 kHz                             Sonicator[1](#tfn2-ijn-2-585){ref-type="table-fn"}          ([@b33-ijn-2-585])

**Legend**

1\. VCX 400, Sonics and Materials Inc., Newtown, CT

2\. Sonopuls 463, Henley International

3\. Precision Acoustic Devices and Panametrics

4\. Leader Electronics Corp., Japan

5\. Sonopuls 474, Henley International

6\. W-385, Heat Systems Ultrasonics, Inc.

7\. Brand not indicated

8\. Cole Palmer Instrument Co, Chicago, IL

9\. Transducer company not indicated

10\. Omnisound 3000, Accelerated Care Plus-Physio Technology Inc., Topeka, KS.

11\. Sonics and Materials, Newtown, CT

12\. ITO Co, 1-23-15, Hakusan, Bunkyo-ku, Tokyu, Japan

13\. Dai-ichi High Frequency, Tokyo, Japan

14\. Model XL2020, Misonix Inc., Farmingdale, NY

15\. Pro Seven 977 to 2000 model, Quark Productos Médicos, Brazil

16\. Noblelife^™^, Duplogen, Suwon, Korea

17\. Piezo Systems, Cambridge, MA

18\. Transducers made in-house

19\. Model S-110, Branson Instruments Inc., Standford, CT

20\. Sofranel, Zurich, Switzerland

21\. VCX 400, Sonics and Materials Inc., Danbury, CT

22\. Sonoplus 590, Enraf-Nonius BV, AV Delft, the Netherlands

23\. Peterson^®^250 Ultrasound Equipment Petaş, Turkey

details not indicated.

FITC-labeled dextrans.

PBS solution was prepared using Milli-Q^®^ water and a phosphate concentration of 0.01 M and NaCl concentration of 0.137 M.

Fluorescein Isothiocyanate (FITC).

**Note:** Apologies are offered for any missing information.

**Abbreviations:** US, ultrasound; Therapeutic, commercially made ultrasound device for heating therapy; TDR, transducer.
